VEGFA and ovarian carcinoma: To validate our immune signature, we studied the independent dataset from Rosario et al.30 which consisted of pretreatment RNAseq from a phase II trial of ICI (pembrolizumab), VEGF blockade (bevacizumab), and DNA damage response inhibitor (metronomic cyclophosphamide) combination therapy for ovarian cancer (GSE206422; NCT02853318).